- 2-17-26 – Cardiovascular Business – FDA clears 12-lead, cable-free home ECG monitoring system
- 2-16-26 – DAIC – Heartbeam earns FDA clearance 12 lead synthesis software assessing arrhythmia
- 2-6-26 – Medical Product Outsourcing – Bryan Humbarger Named Chief Commercial Officer at HeartBeam
- 1-8-26 – Modern Healthcare – FDA clearances and approvals: J&J, Abbott, Edwards Lifesciences
- 12-16-25 – DAIC – Heartbeam earns FDA clearance 12 lead synthesis software
- 12-11-25 – EP Lab Digest – Heartbeam receives FDA clearance first ever cable free synthesized 12 lead ECG home
- 12-11-25 – Cardiac Rhythm News – Heartbeam receives US FDA clearance for at home arrhythmia assessment with cable free 12 lead ECG
- 12-11-25 – BioSpace – Heartbeam receives FDA clearance for first ever cable free synthesized 12 lead ECG for at home arrhythmia assessment
- 12-11-25 – Fierce Biotech – Heartbeam swells turning FDA rejection ECG clearance
- 12-10-25 – RT Magazine – FDA clears Heartbeam cable free 12 lead ECG
- 12-10-25 – Medical Product Outsourcing – Heartbeam wins FDA nod for cable free 12 lead ECG for home arrhythmia assessment
- 12-10-25 – Becker’s Hospital Review – 1st synthesized 12 lead ECG to launch in 2026
- 12-10-25 – Bioworld – Heartbeam wins appeal gains FDA clearance
- 12-10-25 – Medical Device Network – FDA clears Heartbeam at home arrhythmia assessment tool
- 9-15-25 – Fast Company – health wellness design innovation by design 2025
- 9-15-25 – Ainvest – revolutionizing heart health Heartbeam innovative ecg technology
- 9-12-25 – Ainvest – Heartbeam beat disruptive edge home ecg monitoring era digital cardiac care
- 9-11-25 – Cardiac Rhythm News – Heartbeams deep learning algorithms demonstrate high rates of accuracy in detecting arrhythmias
- 9-8-25 – AInvest – Heartbeam deep learning algorithms demonstrate high accuracy arrhythmia detection
- 9-8-25 – BioWorld – Heartbeams portable device matches standard ecg accuracy
- 8-28-25 – AInvest – Heartbeam revolutionizes cardiac care FDA cleared ECG technology
